Key result
Alirocumab reduces coronary plaque progression ~21% vs placebo in heart transplant recipients.
Why the study?
Cardiac allograft vasculopathy remains a major cause of allograft failure after heart transplantation, and the impact of PCSK9 inhibition on CAV progression may vary by baseline lipid-related residual risk.
Does alirocumab attenuate plaque progression in heart transplant recipients with elevated LDL-C and Lp(a)?
RCT (n=114)
Double-blind, placebo-controlled
Randomized
Yes
Does alirocumab attenuate plaque progression in heart transplant recipients with elevated LDL-C and Lp(a)?
Answers are grounded in this paper and cite their sources.
Joint stratification by baseline LDL-C and Lp(a) may identify heart transplant recipients with greater residual lipid risk who derive anti-atherosclerotic benefit from PCSK9 inhibition.
Tweet: In heart transplant recipients, alirocumab attenuated cardiac allograft vasculopathy progression only in patients with concomitantly elevated LDL-C and lipoprotein(a). Lipid phenotype–guided risk stratification may identify those most likely to benefit from PCSK9 inhibition after heart transplantation. #PCSK9inhibition #CAV #HeartTransplantation
No takes yet. Share an insight, caveat, or question.
Terada et al. (2026) conducted an RCT in Cardiac allograft vasculopathy in heart transplant recipients (n=114). Alirocumab vs. Placebo was evaluated on 1-year change in total plaque volume (TPV) (GMR 0.79, 95% CI 0.64 to 0.99, p=0.039). In heart transplant recipients with concomitantly elevated baseline LDL-C and lipoprotein(a), alirocumab attenuated plaque progression compared to placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: